These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 19591405)

  • 21. 90Y-ibritumomab tiuxetan in the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma.
    Fink-Bennett DM; Thomas K
    J Nucl Med Technol; 2003 Jun; 31(2):61-8; quiz 69-70. PubMed ID: 12777454
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma.
    Esmaeli B; McLaughlin P; Pro B; Samaniego F; Gayed I; Hagemeister F; Romaguera J; Cabanillas F; Neelapu SS; Banay R; Fayad L; Wayne Saville M; Kwak LW
    Ann Oncol; 2009 Apr; 20(4):709-14. PubMed ID: 19150940
    [TBL] [Abstract][Full Text] [Related]  

  • 23. B-cell non-Hodgkin lymphoma: PET/CT evaluation after 90Y-ibritumomab tiuxetan radioimmunotherapy--initial experience.
    Ulaner GA; Colletti PM; Conti PS
    Radiology; 2008 Mar; 246(3):895-902. PubMed ID: 18258810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma.
    Witzig TE; White CA; Wiseman GA; Gordon LI; Emmanouilides C; Raubitschek A; Janakiraman N; Gutheil J; Schilder RJ; Spies S; Silverman DH; Parker E; Grillo-López AJ
    J Clin Oncol; 1999 Dec; 17(12):3793-803. PubMed ID: 10577851
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Unsuspected pneumonia detected by increased lung uptake on 111In-ibritumomab tiuxetan scan.
    Hwang M; Joyce JM; Klein H; Hou JZ
    Clin Nucl Med; 2012 Oct; 37(10):1003-5. PubMed ID: 22955077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Logistics of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
    Zimmer AM
    Semin Nucl Med; 2004 Jan; 34(1 Suppl 1):14-9. PubMed ID: 14762740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.
    Witzig TE; Flinn IW; Gordon LI; Emmanouilides C; Czuczman MS; Saleh MN; Cripe L; Wiseman G; Olejnik T; Multani PS; White CA
    J Clin Oncol; 2002 Aug; 20(15):3262-9. PubMed ID: 12149300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome.
    Tsimberidou AM; Murray JL; O'Brien S; Wierda WG; Keating MJ
    Cancer; 2004 May; 100(10):2195-200. PubMed ID: 15139064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 90Y-ibritumomab tiuxetan therapy in allogeneic transplantation in B-cell lymphoma with extensive marrow involvement and chronic lymphocytic leukemia: utility of pretransplantation biodistribution.
    Matesan M; Rajendran J; Press OW; Maloney DG; Storb RF; Cassaday RD; Pagel JM; Oliveira G; Gopal AK
    Nucl Med Commun; 2014 Nov; 35(11):1132-42. PubMed ID: 25076159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of dosimetry in the high activity 90Y-ibritumomab tiuxetan regimens: two cases of abnormal biodistribution.
    Aricò D; Grana CM; Vanazzi A; Ferrari M; Mallia A; Sansovini M; Martinelli G; Paganelli G; Cremonesi M
    Cancer Biother Radiopharm; 2009 Apr; 24(2):271-5. PubMed ID: 19409050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of metabolic response to radioimmunotherapy with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
    Storto G; De Renzo A; Pellegrino T; Perna F; De Falco T; Erra P; Nardelli A; Speranza A; Klain M; Rotoli B; Pace L
    Radiology; 2010 Jan; 254(1):245-52. PubMed ID: 20032155
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia.
    Schilder R; Molina A; Bartlett N; Witzig T; Gordon L; Murray J; Spies S; Wang H; Wiseman G; White C
    Cancer Biother Radiopharm; 2004 Aug; 19(4):478-81. PubMed ID: 15453962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Zevalin: 90yttrium labeled anti-CD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin's lymphoma.
    Krasner C; Joyce RM
    Curr Pharm Biotechnol; 2001 Dec; 2(4):341-9. PubMed ID: 11762415
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma.
    Maza S; Kiewe P; Munz DL; Korfel A; Hamm B; Jahnke K; Thiel E
    Neuro Oncol; 2009 Aug; 11(4):423-9. PubMed ID: 19060176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma.
    Weigert O; Illidge T; Hiddemann W; Dreyling M
    Cancer; 2006 Aug; 107(4):686-95. PubMed ID: 16826593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin).
    Tennvall J; Fischer M; Bischof Delaloye A; Bombardieri E; Bodei L; Giammarile F; Lassmann M; Oyen W; Brans B; ; ;
    Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):616-22. PubMed ID: 17323056
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma.
    Witzig TE; White CA; Gordon LI; Wiseman GA; Emmanouilides C; Murray JL; Lister J; Multani PS
    J Clin Oncol; 2003 Apr; 21(7):1263-70. PubMed ID: 12663713
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma.
    Doolittle ND; Jahnke K; Belanger R; Ryan DA; Nance RW; Lacy CA; Tyson RM; Haluska M; Hedrick NA; Varallyay C; Neuwelt EA
    Leuk Lymphoma; 2007 Sep; 48(9):1712-20. PubMed ID: 17786706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of ⁹⁰Yttrium-ibritumomab tiuxetan in relapsed/refractory extranodal marginal-zone lymphoma.
    Vanazzi A; Grana C; Crosta C; Pruneri G; Rizzo S; Radice D; Pinto A; Calabrese L; Paganelli G; Martinelli G
    Hematol Oncol; 2014 Mar; 32(1):10-5. PubMed ID: 23696416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia.
    Wiseman GA; Leigh BR; Erwin WD; Sparks RB; Podoloff DA; Schilder RJ; Bartlett NL; Spies SM; Grillo-López AJ; Witzig TE; White CA
    Cancer Biother Radiopharm; 2003 Apr; 18(2):165-78. PubMed ID: 12804042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.